Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: Towards addressing the missing heritability in pharmacogenetic phenotypes?

Pharmacogenetics and Genomics

Volumn 23, Issue 11, 2013, Pages 591-596

  Micheli, Janine E ^a   Chinn, Leslie W ^a   Shugarts, Sarah B ^a   Patel, Ashish ^a   Martin, Jeffrey N ^a,b   Bangsberg, David R ^c   Kroetz, Deanna L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

CYP2B6; Human immunodeficiency virus; Nevirapine; Pharmacogenetics; Pharmacokinetics

Indexed keywords

NEVIRAPINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG RELEASE; ETHNIC DIFFERENCE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HERITABILITY; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; AFRICAN AMERICANS; AGED; ANTI-HIV AGENTS; ARYL HYDROCARBON HYDROXYLASES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC VARIATION; GENOTYPE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; P-GLYCOPROTEIN; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 84886583431     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32836533a5     Document Type: Article

References (33)

1. Motulsky AG. Drug reactions, enzymes and biochemical genetics. JAMA 1957; 165: 835-837.
2. Carson PE, Flanagan CL, Ickes CE, Alving AS. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science 1956; 124: 484-485.
3. Kalow W. Genetic factors in relation to drugs. Annu Rev Pharmacol 1964; 5: 9-26.
4. Wesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 1989; 41: 535-552.
5. Kalow W, Endrenyi L, Tang B. Repeat administration of drugs as a means to assess the genetic component in pharmacological variability. Pharmacology 1999; 58: 281-284.
6. Ozdemir V, Kalow W, Tothfalusi L, Bertilsson L, Endrenyi L, Graham JE. Multigenic control of drug response and regulatory decision-making in pharmacogenomics: the need for an upper-bound estimate of genetic contributions. Curr Pharmacogenomics 2005; 3: 53-71.
7. Ozdemir V, Kalow W, Tang BK, Paterson AD,Walker SE, Endrenyi L, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373-388.
8. Leabman MK, Giacomini KM. Estimating the contribution of genes and environment to variation in renal drug clearance. Pharmacogenetics 2003; 13: 581-584.
9. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2009. pp. 1-161.
10. Gandhi M, Benet LZ, Bacchetti P, Kalinowski A, Anastos K,Wolfe AR, et al. Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. J Acquir Immune Defic Syndr 2009; 50: 482-491.
11. Cooper CL, Van Heeswijk RPG. Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. HIV Med 2007; 8: 1-7.
12. Riska P, Lamson M, Macgregor T, Sabo J, Hattox S, Pav J, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans abstract. Pharmacology 1999; 27: 895-901.
13. Mahungu T, Smith C, Turner F, Egan D, Youle M, Johnson M, et al. Cytochrome P450 2B6 516G-T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. HIV Med 2009; 10: 310-317.
14. Penzak SR, Kabuye G, Mugyenyi P, Mbamanya F, Natarajan V, Alfaro RM, et al. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. HIV Med 2007; 8: 86-91.
15. Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, et al. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J Infect Dis 2009; 199: 872-880.
16. Ciccacci C, Borgiani P, Ceffa S, Sirianni E, Marazzi MC, Altan AM, et al. Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. Pharmacogenomics 2007; 11: 23-31.
17. Varatharajan L, Thomas SAa. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res 2009; 82:A99-109.
18. Moss AR, Hahn JA, Perry S, Charlebois ED, Guzman D, Clark RA, et al. Adherence to highly active antiretroviral therapy in the homeless population in San Francisco: a prospective study. Clin Infect Dis 2004; 39: 1190-1198.
19. Tsai H-J, Choudhry S, Naqvi M, Rodriguez-Cintron W, Burchard EG, Ziv E. Comparison of three methods to estimate genetic ancestry and control for stratification in genetic association studies among admixed populations. Hum Genet 2005; 118: 424-433.
20. Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
21. Falush D, Stephens M, Pritchard JK. Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 2003; 164: 1567-1587.
22. Mistri HN, Jangid AG, Pudage A, Gomes N, Sanyal M, Shrivastav P. High throughput LC-MS/MS method for simultaneous quantification of lamivudine, stavudine and nevirapine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 853: 320-332.
23. Viramune s (nevirapine) Tablets [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2005.
24. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8: 283-289.
25. Venables WN, Ripley BD. Modern applied statistics with S-plus. New York, NY: Springer-Verlag; 1994.
26. R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2012.
27. De Vries-sluijs TEMS, Dieleman JP, Arts D, Huitema ADR, Beijnen JH, Schutten M, et al. Concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42: 599-605.
28. Ramachandran G, Ramesh K, Hemanth Kumar AK, Jagan I, Vasantha M, Padmapriyadarsini C, et al. Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic South Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. J Antimicrob Chemother 2009; 63: 841-843.
29. Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, et al. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. AIDS 2007; 21: 2191-2199.
30. Lang T, Klein K, Fischer J, Nü ssler AK, Neuhaus P, Hofmann U, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399-415.
31. Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, et al. Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. Ther Drug Monit 2012; 34: 153-159.
32. Chen J, Sun J, Ma Q, Yao Y,Wang Z, Zhang L, et al. CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. Ther Drug Monit 2010; 32: 573-578.
33. Ghannoum MAa, Mukherjee PK, Jurevic RJ, Retuerto M, Brown RE, Sikaroodi M, et al. Metabolomics reveals differential levels of oral metabolites in HIV-infected patients: toward novel diagnostic targets. OMICS 2013; 17: 5-15.